SARASOTA, Fla., June 30, 2004 (PRIMEZONE) -- The following is an investment opinion issued by eLocity Inc.:
Bad Toys, Inc. (OTCBB:BTOI), Euro Tech Holdings Company Limited (Nasdaq: CLWT) and Xenova Group plc (LSE:XEN) (Nasdaq:XNVA).
Bad Toys, Inc. (OTCBB:BTOI), a Nevada Corporation engaged in the business of manufacturing and selling custom V-Twin motorcycles, custom street rods and providing brokerage service to custom cars, classic cars, and motorcycle owners, announced it has entered into a Letter of Intent to acquire the majority interest in American Eagle Manufacturing Company, Inc. (OTCBB:AEMC). Upon completion of the acquisition, Bad Toys will not only increase its gross assets by approximately $3 million but will also increase its clientele and its market share. BTOI currently trades at around 2.00 a share.
On the Nasdaq gaining big Tuesday was, Euro Tech Holdings Company Limited (Nasdaq:CLWT). The company reported Tuesday its financial results for the 12-month period ending December 31, 2003 and announced a stock dividend to the holders of its Ordinary Shares. The Company's revenues for the fiscal year ended December 31, 2003 ("Fiscal 2003") were approximately $27,442,000 compared to approximately $23,497,000 in the Company's fiscal year ended December 31, 2002 ("Fiscal 2002"), an approximate 17% increase. Net income for Fiscal 2003 was approximately $531,000, an approximate 6% increase from Fiscal 2002 net income of approximately $500,000. CLWT traded up $4.739 (154.82%) Tuesday on volume of 10,119,245 to close at $7.80 a share.
Also trading well Tuesday was Xenova Group plc (LSE:XEN) (Nasdaq:XNVA). XNVA traded 10,485,716 shares Tuesday to close at $2.62 up $0.83 (46.37%) a share. Xenova Group plc is a UK-based biopharmaceutical company focused on the development of novel drugs to treat cancer and addiction with a secondary focus in immunotherapy. The Company has a broad pipeline of products in clinical development, including three cancer programmes: its lead product TransMIDTM, for the treatment of high-grade glioma, is in Phase III trials, and its novel DNA targeting agents and XR303 are both in Phase I for cancer indications.
About eLocity Inc: eLocity owns and operates three financial websites for investors.
-- Bell2Bell.com, http://www.bell2bell.com/. Bell2Bell features news stories, rumors, the InvestBoard and more.
-- PennyPicks.com, http://www.pennypicks.com/. Featuring active message boards for the penny stock trader, rumors and more.
-- StockGrid.com, http://www.stockgrid.com/. Visit this site for our daily top stock "GRID Makers". We rank stocks on volume, message board activity, sentiment and trend forecast.
Sign up for FREE at any of the sites above.
The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, is here after referred to as "the company". The company received compensation for this newsletter service for Bad Toys Inc. only. The compensation is six thousand free trading shares of BTOI from a non-affiliated third party, Investor Response LLC. Because the company received compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.
The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.
The company relies exclusively on information gathered from the client, public filings on client, press releases and client's web site. Investors should use the information contained in this publication as a starting point for conducting additional research on the featured client in order to allow the investor to form his or her own opinion regarding the featured clients. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.
Investment in the clients reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.
The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.